Epidemiology Data

May 2023

IMPORTANT NOTICE: For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.
OVERVIEW OF EPIDEMIOLOGY DATA

ONCOLOGY

GASTROENTEROLOGY (GI)

RARE GENETIC & HEMATOLOGY
<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Total Global Eligible Population</th>
<th>Geographies included</th>
</tr>
</thead>
<tbody>
<tr>
<td>NINLARO (ixazomib) capsules</td>
<td>R/R 2L+ Multiple Myeloma</td>
<td>~104,000&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Japan, US, EU5, China</td>
</tr>
<tr>
<td>ALUNBRIG™</td>
<td>1L ALK+ NSCLC</td>
<td>~32,000&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Japan, US, EU5, China</td>
</tr>
<tr>
<td>ADCETRIS</td>
<td>HL – Front Line, ASCT Consolidation, 2L+; TCL - PTCL &amp; R/R CTCL</td>
<td>~20,000&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Japan, EU5, China</td>
</tr>
<tr>
<td>ICLUSIG® (ponatinib) tablets</td>
<td>CML, ALL</td>
<td>~7,000&lt;sup&gt;4&lt;/sup&gt;</td>
<td>US</td>
</tr>
<tr>
<td>EXKIVITY® (mobocertinib)</td>
<td>1L/2L EGFR Exon20 Insertion+ NSCLC</td>
<td>~4,500&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Japan, US, EU5</td>
</tr>
</tbody>
</table>

<sup>1</sup> R/R 2L+ MM label eligible patients; 2. ALK+ tested patients; 3. CD30+ label eligible patients - regulatory approval includes Stage IV/ITT Front Line Patients and High Risk HL consolidation patients; 4. total CML and Ph+ ALL 5. EGFR Exon20 insertion+ mNSCLC patients whose disease has progressed on or after platinum-based chemotherapy.

Source: Takeda estimates. EU5 = France, Spain, Germany, Italy, UK
OVERVIEW OF EPIDEMIOLOGY DATA

ONCOLOGY

GASTROENTEROLOGY (GI)

RARE GENETIC & HEMATOLOGY
ULCERATIVE COLITIS (UC)

| Source: Takeda estimate. Note: Numbers are rounded. |

- **Diagnosed Prevalence**
  - Japan: ~3,990K
  - GEM (incl. China): 1,556K
  - EUCAN: 1,298K
  - US: 795K

- **Treated**
  - Japan: ~3,500K
  - GEM (incl. China): 1,400K
  - EUCAN: 1,018K
  - US: 780K

- **Patients on biologic therapies**
  - Japan: ~500K
  - GEM (incl. China): 32K
  - EUCAN: 107K
  - US: 225K
  - Total: 32K

CROHN’S DISEASE (CD)

Diagnosed Prevalence

- Japan: ~847K
- GEM: 1,053K
- EUCAN: 58K
- US: ~2,370K

Treated

- Japan: ~760K
- GEM: 804K
- EUCAN: 57K
- US: ~2,270K

Patients on biologic therapies

- Japan: ~156K
- GEM: 321K
- EUCAN: 32K
- US: ~760K

Source: Takeda estimate. Note: Numbers are rounded.
Crohn’s Disease (CD) Patients

CD Patients with Perianal Fistula

Complex Perianal Fistula (CPF) Patients

~1,960K
847K

~324K
178K

~213K
139K

Source: Takeda estimate. Note: Numbers are rounded.
OVERVIEW OF EPIDEMIOLOGY DATA

- ONCOLOGY
- GASTROENTEROLOGY (GI)
- RARE GENETIC & HEMATOLOGY
HEREDITARY ANGIOEDEMA

Prevalence: 70-130K
Diagnosed: 24-31K
Treated: 20-26K

Source: Takeda estimate. Note: Numbers are rounded.
GAUCHER’S DISEASE:
GLOBAL, CHINA/INDIA NOT INCLUDED

Prevalence
~34-35K prevalent patients

Diagnosed
~24K un-diagnosed patients (70%)
~10K diagnosed patients (30%)

Source: Takeda estimate. Note: Numbers are rounded.
FABRY’S DISEASE: EX-US REGION, CHINA/INDIA NOT INCLUDED

Prevalence

~53-54K prevalent Fabry patients

Diagnosed

~40K un-diagnosed patients (74%)

~14K diagnosed Fabry patients (26%)

Source: Takeda estimate. Note: Numbers are rounded.
HUNTER’S DISEASE: GLOBAL, INDIA/CHINA NOT INCLUDED

MPS II Patients

- Prevalence: 5K
- Diagnosed: 2-3K
- Treated: 2K

Source: Takeda estimates. Note: Numbers are rounded.
HEMOPHILIA A

Hemophilia A without inhibitors

~142K

Prevalence

~116K

Diagnosed

~92K

Treated

18K

69K

50K

46K

48K

40K

30K

17K

17K

5K

5K

5K

Source: Takeda estimate. Note: Numbers are rounded.
RARE CYTOMEGALOVIRUS (CMV) INFECTION IN POST-TRANSPLANT

Source: Takeda estimate. Last update: March 2023; covering 45 countries

≈33k
≈81k
≈132k
≈8k
≈33k
≈0k
≈2k
≈7k
≈44k
≈176k

Total Allogenic-HSCT and Solid Organ Transplant

Solid Organ Transplants

Allogeneic Hemopoietic Stem Cell Transplant

≈1/4 of transplant patients experience CMV infections

Legend:
- Heart
- Liver
- Intestine
- Lungs
- Kidney
- Pancreas

CMV infection in post-transplant patients are 100% diagnosed & treated

Focus of LIVTENCITY

Source: Takeda estimate. Last update: March 2023; covering 45 countries